Business Wire
-
Approval Of US Pilot Clinical Trial To Evaluate AclarusDx™, The Exonhit Investigational Test For Alzheimer’s Disease Diagnosis
10/27/2011
Exonhit (Paris:ALEHT) announced today the Institutional Review Board (IRB) approval of Exonhit sponsored pilot clinical trial aimed at evaluating the performance of AclarusDx™, a blood based investigational diagnostic test, in US-based patients suffering from memory impairment and newly referred to a reference Memory Center for Alzheimer’s Disease (AD) diagnostic workup. This study will be conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health.
-
BioVigilant Submits Drug Master Files To U.S. FDA For Instantaneous Microbial Detection Systems
9/1/2011
BioVigilant Systems, Inc. (www.biovigilant.com), inventors of Instantaneous Microbial Detection™, announced today it has filed Type V Drug Master Files (DMFs) for its IMD-A® 300 series of rapid biologic detection systems for real-time environmental air monitoring in pharmaceutical manufacturing environments.
-
New Survey Finds Life Sciences Companies Struggling To Accurately Forecast Spending For Clinical Studies
8/1/2011
ClearTrial recently announced the results of a new survey of life sciences professionals charged with forecasting and budgeting clinical studies at small, mid-sized, and Top 20 biopharmaceutical and medical device companies.
-
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With Abbott
3/22/2011
Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it has entered into a collaboration agreement with Abbott (NYSE:ABT) under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.
-
Mirrx Therapeutics A/S Secures Seed Financing For Development Of Novel MicroRNA-Blocking Technology
2/4/2010
Mirrx Therapeutics today announced that it has closed on a seed financing round that will enable the company to achieve in vivo proof of concept for its microRNA-blocking “Blockmir” technology, as well as to strengthen its intellectual property portfolio.
-
Pfizer Announces Global Research Network
11/9/2009
Pfizer Inc today announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth.
-
Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research
8/20/2009
Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access, the innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation.
-
Top 5 Industries Most At Risk Of Web-Based Malware
11/11/2008
ScanSafe, the pioneer and leading provider of SaaS Web Security, today releases its report ‘The Vertical Risk’ which reveals the top 5 industries at risk of Web-delivered malware as well as an analysis of the types and severity of the malware encountered.
-
Monogram Biosciences Announces HER2:HER3 Heterodimer And HER3/PI3K VeraTag™ Assays Are Now Available For Use In Development Of Cancer Therapeutics
11/11/2008
Monogram Biosciences, Inc. today announced that additional EGFR/HER assays have been successfully tested in sets of fixed human tumors and are now available for use in drug development programs.
-
INNO-406 Demonstrates Positive Clinical Responses In Phase 1 Trial In Patients With Chronic Myeloid Leukemia
11/11/2008
CytRx Corporation, today announced that INNO-406, CytRx’s potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML).
This website uses cookies to ensure you get the best experience on our website. Learn more